Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > AZD3759

AZD3759

AZD3759 structure

AZD3759 

structure

Description

AZD3759 is a potent, oral active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively.


AZD-3759 is under investigation in clinical trial NCT03360929 (Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759).|Zorifertinib is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, zorifertinib binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR-mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

AZD3759 Basic Attributes

459.9

459.147339

67SX9H68W2

C118289

Characteristics

79.8

4.1

white to off-white solid

1.4±0.1 g/cm3

192.4 °C(醇、酯), 193.3 °C (水)

299.3±30.1 °C

1.632

3 years -20℃ powder, 6 months -80℃ in solvent

Drug Information

4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 2,4-dimethylpiperazine-1-carboxylate

Computed Properties

Molecular Weight:459.9
XLogP3:4.1
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:8
Rotatable Bond Count:5
Exact Mass:459.1473455
Monoisotopic Mass:459.1473455
Topological Polar Surface Area:79.8
Heavy Atom Count:32
Complexity:649
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of AZD3759

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.